Gilead Sciences posts strong growth on antiviral performance
This article was originally published in Scrip
Executive Summary
Gilead Sciences has reported a 24% increase in product sales to $1.8 billion for the first quarter following strong growth of its antiviral franchise. Net income was $855 million, an increase of 45%.